Journal
Journal for Immunotherapy of Cancer
Publication Date
3-1-2022
Volume
10
Issue
3
First Page
e004233
Document Type
Open Access Publication
DOI
10.1136/jitc-2021-004233
Rights and Permissions
Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022 Mar;10(3):e004233. doi.org/10.1136/jitc-2021-004233. https://jitc.bmj.com/content/10/3/e004233 © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Lheureux, Stephanie; McCourt, Carolyn; and et al, "Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer." Journal for Immunotherapy of Cancer. 10, 3. e004233 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11541
